Research To Practice

•

チャンネル • 10個の番組

科学

科学

アップデート：毎週
科学

科学

アップデート：毎月
科学

科学

アップデート：月2回
科学

科学

アップデート：毎週
科学

科学

アップデート：毎週
科学

科学

アップデート：毎週
科学

科学

アップデート：毎週

8月24日

For Oncology Nurses: Pancreatic Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics: Introduction (0:00)Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)Utility of Tumor Treating Fields in PAD Management (1:13:58) CME information and select publications
8月12日 · ビデオ

Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42) Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23) Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01) Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22) Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37) CME information and select publications
8月20日

Gastroesophageal Cancers — Year in Review Series on Relevant New Datasets and Advances

Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics: Introduction (0:00)Biomarker Evaluation in Localized and Metastatic Disease (1:49)Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37)Other Available Therapeutic Approaches — Dr Shitara (33:22) CME information and select publications
6日前 · ビデオ

For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics: Introduction (0:00) Overview of Prostate Cancer (3:00) Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12) Potential Role of Capivasertib in Metastatic HSPC (27:22) Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39) Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14) CME information and select publications
2025/09/05 · ビデオ

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu

Featuring an interview with Prof Xavier Leleu including the following topics: Introduction: Historical treatment advances in multiple myeloma (MM) (0:00) Contemporary treatment for patients with newly diagnosed MM who are eligible for transplant (13:18) Prognosis and life expectancy for patients with MM (19:39) Mechanistic differences among anti-CD38 monoclonal antibodies (27:05) Routes of administration of anti-CD38 monoclonal antibodies (30:21) Background and treatment of smoldering myeloma (41:05) Treatment for older patients with newly diagnosed MM who are not eligible for transplant (46:41) NCPD information and select publications
8月28日

Metastatic Triple-Negative Breast Cancer — Patterns of Care

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics: Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)First-Line Therapy (PD-L1 Negative) (6:53)First-Line Therapy (PD-L1 Positive) (23:40)Second-Line Therapy (Sequencing) (34:08)Adverse Events with TROP2-Targeting ADCs (43:43) CME information and select publications
8月26日

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics: Introduction: Lymphoma Survivorship (0:00)Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14) CME information and select publications
7月30日

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3

Featuring perspectives from Dr Joshua K Sabari, including the following topics: Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study. ESMO 2025;Abstract 2020P. (8:30)Schram AM et al. Beamion PANTUMOR-1: Rationale and design of a phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol 2026;22(7):795-803. (12:53)Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654. (19:40)Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648. (21:41)Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137. (22:59)Jänne PA et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic NSCLC with or without brain metastases: A secondary analysis of randomized clinical trials. JAMA Netw Open 2025;8(11):e2543107. (24:37) CME information and select publications
7月23日

For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics: Introduction (00:00)Overview of Ovarian Cancer (OC) (2:12)Role of PARP Inhibitors in Advanced OC (4:56)Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)Role of Relacorilant in Advanced OC (57:08)Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12) NCPD information and select publications
8月24日

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction: San Antonio Memories (0:00)PI3K/AKT/PTEN Alterations and Therapies (7:18)Capivasertib (20:22)Gedatolisib (34:08)Inavolisib (47:07)New Agents and Ongoing Trials (52:34) CME information and select publications

CME education for oncology clinicians. Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.